Bionano Announces Publication Showing that OGM Identifies Genetic Aberrations in Sarcoma Samples that May Lead to Improved Diagnosis but were Missed by Classical Cytogenetics
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq:BNGO), today announced the publication of a peer-reviewed study that compared optical genome mapping (OGM) to classical cytogenetic techniques used for analysis of solid tumor cancer samples consisting of soft tissue and bone sarcomas, including fluorescence in situ hybridization (FISH) and karyotyping (KT). OGM demonstrated high levels of concordance with FISH and KT but was also shown to exclusively detect alterations in known oncogenes and tumor suppressor genes and to identify additional pathogenic aberrations, including chromothripsis and chromoplexy, that were not detected by multiple other cytogenetic methods.